MIM Fertility Raises $2M in Seed Funding to Revolutionize IVF with AI-Powered EMBRYOAID

MIM Fertility is thrilled to announce the successful raise of $2,000,000 in its latest funding round—a pivotal milestone that will accelerate our mission to revolutionize the fertility industry through advanced AI and machine learning innovations. As a deeptech company at the forefront of healthcare technology, we develop AI-powered, cutting-edge applications designed to optimize the workflows of IVF clinics and laboratories. Our flagship product, EMBRYOAID by MIM Fertility, stands as a testament to our commitment to improving patient outcomes by providing a state-of-the-art platform that assesses the implantation potential of human embryos using either a single image or time lapse video. EMBRYOAID features fully automated day-5 embryo evaluations, advanced IVF analytics, integrated messaging systems, and seamless connectivity with various time-lapse incubators, ensuring a comprehensive and efficient approach to embryo assessment. Founded and led by visionaries, our team comprises more than 25 professionals including award-winning Polish ML experts and internationally recognized fertility specialists, most of whom hold PhDs and bring unparalleled expertise and dedication to our mission. This recent funding injection will be strategically deployed to further enhance our AI/ML capabilities, expand our product offerings, and integrate even more sophisticated analytical modules into our platform, thereby reducing the time and cost associated with fertility procedures while ensuring higher accuracy in diagnosis and treatment. As a proud member of the Business Advisory Group to the President of the EC under the Global Gateway Programme, we remain committed to bridging the gap between deeptechnology and human healthcare, ultimately making a transformative impact on the future of fertility treatments worldwide.